Theravance Biopharma (NASDAQ:TBPH) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Theravance Biopharma (NASDAQ:TBPH) in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has a $15.00 price target on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Theravance Biopharma’s Q4 2024 earnings at ($0.17) EPS, FY2024 earnings at ($1.01) EPS, FY2025 earnings at ($0.69) EPS, FY2026 earnings at ($0.42) EPS, FY2027 earnings at ($0.43) EPS, FY2028 earnings at $1.11 EPS and FY2029 earnings at $3.87 EPS.

Theravance Biopharma Price Performance

Shares of NASDAQ:TBPH opened at $9.27 on Tuesday. The firm has a market capitalization of $455.84 million, a price-to-earnings ratio of -9.18 and a beta of 0.21. The business’s 50 day simple moving average is $9.34 and its 200-day simple moving average is $8.92. Theravance Biopharma has a 12 month low of $7.44 and a 12 month high of $10.90.

Theravance Biopharma (NASDAQ:TBPH) last posted its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.26). The firm had revenue of $18.75 million for the quarter, compared to analysts’ expectations of $29.90 million. Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. On average, equities analysts anticipate that Theravance Biopharma will post -1.09 earnings per share for the current year.

Insider Buying and Selling at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the sale, the senior vice president now owns 309,565 shares in the company, valued at approximately $2,786,085. This represents a 1.28 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 6.90% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Newtyn Management LLC boosted its stake in Theravance Biopharma by 5.7% in the 4th quarter. Newtyn Management LLC now owns 4,757,403 shares of the biopharmaceutical company’s stock worth $44,767,000 after buying an additional 258,337 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Theravance Biopharma by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 862,802 shares of the biopharmaceutical company’s stock worth $8,121,000 after acquiring an additional 4,823 shares during the period. D. E. Shaw & Co. Inc. boosted its position in shares of Theravance Biopharma by 9.0% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 833,943 shares of the biopharmaceutical company’s stock worth $7,847,000 after acquiring an additional 69,178 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Theravance Biopharma by 20.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 553,713 shares of the biopharmaceutical company’s stock valued at $5,211,000 after purchasing an additional 95,304 shares during the period. Finally, Nuveen Asset Management LLC increased its position in Theravance Biopharma by 10.9% during the fourth quarter. Nuveen Asset Management LLC now owns 495,727 shares of the biopharmaceutical company’s stock worth $4,665,000 after purchasing an additional 48,635 shares during the last quarter. Hedge funds and other institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.